Ethosuximide (All indications) updated on 04-22-2025

Small for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9792
R35056		 Kilic (Ethosuximide) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Small for gestational age (birth weight <10% percentile for the gestational birth week) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 10.16 [0.20;515.55] C
excluded (control group) 		0/1   78/876 78 1
ref
S9793
R35059		 Kilic (Ethosuximide) (Controls unexposed NOS) (Mixed indications), 2014 Small for gestational age (birth weight <10% percentile for the gestational birth week) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: No 9.35 [0.19;471.15] C
excluded (control group) 		0/1   65,118/673,844 65,118 1
ref
S9794
R35062		 Kilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 Small for gestational age (birth weight <10% percentile for the gestational birth week) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 7.87 [0.16;397.17] C 0/1   594/5,275 594 1
ref
Total 1 studies 7.87 [0.16;397.17] 594 1
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 1 7.87[0.16; 397.17]59410%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate0.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide) (Controls unexposed, sick) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 7.87[0.16; 397.17]5941 -NAKilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 7.87[0.16; 397.17]5941 -NAKilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 1 Tags Adjustment   - No  - No 7.87[0.16; 397.17]5941 -NAKilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 1 Controls   - epilepsy indication  - epilepsy indication 7.87[0.16; 397.17]5941 -NAKilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 7.87[0.16; 397.17]5941 -NAKilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 10.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9792, 9793

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 9.35[0.19; 471.15]65,1181 -NAKilic (Ethosuximide) (Controls unexposed NOS) (Mixed indications), 2014 1 unexposed, sick controlsunexposed, sick controls 7.87[0.16; 397.17]5941 -NAKilic (Ethosuximide) (Controls unexposed, sick) (Mixed indications), 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale10.16[0.20; 515.55]781 -NAKilic (Ethosuximide) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 10.510.01.0